Activated vitronectin as a target for anticancer therapy with human antibodies

Cancer Immunology, Immunotherapy

Volumn 53, Issue 9, 2004, Pages 799-808

  Bloemendal, Haiko J ^a   De Boer, Hetty C ^a   Koop, Elianne A ^a   Van Dongen, Alice J ^a   Goldschmeding, Roel ^a   Landman, Wil J M ^b   Logtenberg, Ton ^a   Gebbink, Martijn F B G ^a   Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GD ANIMAL HEALTH   (Netherlands)

Author keywords

Activated vitronectin; Human antibody VN18; Tumor targeting

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY VN18; IODINE 123; UNCLASSIFIED DRUG; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; CHICKEN; CONTROLLED STUDY; DRUG TARGETING; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; ROUS SARCOMA ONCOVIRUS; TISSUE DISTRIBUTION;

EID: 3843057077     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0506-z     Document Type: Article

References (44)

1. Azzoli CG, Krug LM, Miller VA, Kris MG, Mass R (2002) Trastuzumab in the treatment of non-small cell lung cancer. Sem Oncol 29:59-65
2. Bittorf SV, Williams EC, Mosher DF (1993) Alteration of vitronectin: characterization of changes induced by treatment with urea. J Biol Chem 268:24838-24846
3. Bloemendal HJ, Logtenberg T, Voest EE (1999) New strategies in anti-vascular cancer therapy. Eur J Clin Inves 29:802-809
4. Boel E, Verlaan S, Poppelier MJ, Westerdaal NA, Van Strijp JA, Logtenberg T (2000) Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments. J Immunol Methods 239:153-166
5. Boudreau N, Bissell MJ (1998) Extracellular matrix signaling: integration of form and function in normal and malignant cells. CurrOpin Cell Biol 10:640-646
6. Bryan RW (1959) Quantitative biological experimentation in the virus and cancer fields. J Natl Cancer Inst 22:129
7. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P (1996) Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 62:260-267
8. Carreiras F, Cruet S, Staedel C, Sichel F, Gauduchon P (1999) Human ovarian adenocarcinoma cells synthesize vitronectin and use it to organize their adhesion. GynecolOncol 72:312-322
9. Davis GE, Bayless KJ, Davis MJ, Meininger GA (2000) Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol 156:1489-1498
10. de Boer HC, Preissner KT, Bouma BN, de Groot PG (1992) Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 267:2264-2268
11. de Kruif J, Terstappen L, Boel E, Logtenberg T (1995) Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc Natl Acad Sci USA 92:3938-3942
12. de Kruif J, Storm G, van Bloois L, Logtenberg T (1996) Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Lett 399:232-236
13. Fidler IJ (1991) Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 10:229-243
14. Gladson CL, Cheresh DA (1991) Glioblastoma expression of vitronectin and the alpha v beta 3 integrin: adhesion mechanism for transformed glial cells. J Clin Invest 88:1924-1932
15. Graham RC Jr, Karnovsky MJ (1966) The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histoch Cytochem 14:291-302
16. Gyles NR, Miley JL, Brown CJ (1967) Size, score and speed of development of tumors in chickens in response to subcutaneous inoculations with Rous sarcoma virus. Poult Sci 46:789-795
17. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593-1611
18. Hoffman RM (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17:343-359
19. Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, van der VuurstdeVries AR, Loyson SA, Helfrich W, BergeHenegouwen GP, van Meijer M, de Kruif J, Logtenberg T (1999) A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 17:276-281
20. Isik FF, Gibran NS, Jang YC, Sandell L, Schwartz SM (1998) Vitronectin decreases microvascular endothelial cell apoptosis. J Cell Physiol 175:149-155
21. Jang YC, Arumugam S, Ferguson M, Gibran NS, Isik FF (1998) Changes in matrix composition during the growth and regression of human hemangiomas. J Surg Res 80:9-15
22. Jaskiewicz K, Chasen MR, Robson SC (1993) Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res 13:2229-2237
23. Kanse SM, Kost C, Wilhelm OG, reasen PA, Preissner KT (1996) The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224:344-353
24. Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17:279-284
25. Kost C, Stuber W, Ehrlich HJ, Pannekoek H, Preissner KT (1992) Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation. J Biol Chem 267:12098-12105
26. Linder S, Castanos-Velez E, von Rosen A, Biberfeld P (2001) Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology 48:1321-1327
27. Loridon-Rosa B, Vielh P, Cuadrado C, Burtin P (1988) Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. Am J Clin Pathol 90:7-16
28. Lukashev ME, Werb Z (1998) ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 8:437-441
29. Piccart-Gebhart MJ (2001) Herceptin: the future in adjuvant breast cancer therapy. Anticancer Drugs 12[Suppl 4]:S27-33, S27-S33
30. Preissner KT, Seiffert D (1998) Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 89:1-21
31. Preissner KT, Wassmuth R, Muller-Berghaus G (1985) Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J 231:349-355
32. Preissner KT, Zwicker L, Muller-Berghaus G (1987) Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum. Biochem J 243:105-111
33. Preissner KT, May AE, Wohn KD, Germer M, Kanse SM (1997) Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodelling. Thromb Haemost 78:88-95
34. Schvartz I, Seger D, Shaltiel S (1999) Vitronectin. Int J Biochem Cell Biol 31:539-544
35. Seiffert D (1997) Constitutive and regulated expression of vitronectin. Histol Histopathol 12:787-797
36. Seiffert D, Smith JW (1997) The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272:13705-13710
37. Sieweke MH, Stoker AW, Bissell MJ (1989) Evaluation of the cocarcinogenic effect of wounding in Rous sarcoma virus tumorigenesis. Cancer Res 49:6419-6424
38. Tomasini BR, Mosher DF (1988) Conformational states of vitronectin: preferential expression of an antigenic epitope when vitronectin is covalently and noncovalentlycomplexed with thrombin-antithrombin III or treated with urea. Blood 72:903-912
39. Tomasini BR, Mosher DF (1991) Vitronectin. Prog Hemost Thromb 10:269-305
40. Uhm JH, Dooley NP, Kyritsis AP, Rao JS, Gladson CL (1999) Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin Cancer Res 5:1587-1594
41. Visser GW, Klok RP, Gebbinck JW, ter Linden T, van Dongen GA, Molthoff CF (2001) Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med 42:509-519
42. Waldmann TA, Levy R, Coller BS (2000) Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology 2000:394-408
43. Waltz DA, Chapman HA (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269:14746-14750
44. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M (1988) Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct 13:281-292